Arrowhead Pharmaceuticals Financial Ratios
NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
62.75+2.01 (+3.31%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arrowhead Pharmaceuticals ratio analysis
Arrowhead Pharmaceuticals earned a net margin of -0.2% in FY 2025, up from -16882.4% a year earlier. Return on equity reached -0.3%, meaning Arrowhead Pharmaceuticals generated -0.00 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Arrowhead Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | — | — | 44.35 | — | — | — |
| Price / sales | 5.82 | 634.85 | 11.92 | 14.33 | 46.96 | 50.16 | 17.02 | 99.33 | 10.19 | 2,834.05 |
| Price / book | 10.37 | 12.16 | 10.57 | 8.74 | 15.89 | 9.56 | 11.74 | 16.74 | 3.93 | 4.69 |
| Operating margin | 11.9% | -16,927.1% | -85.2% | -73.4% | -107.8% | -105.9% | 36.3% | -346.5% | -117.8% | -51,627.1% |
| Net margin | -0.2% | -16,882.4% | -85.3% | -72.4% | -101.9% | -96.1% | 40.3% | -337.3% | -109.5% | -51,614.6% |
| Free cash flow margin | 18.9% | -17,018.3% | -137.3% | -77.7% | 106.8% | -122.5% | 95.4% | -301.3% | -101.4% | -43,129.2% |
| Return on equity (ROE) | -0.3% | -323.3% | -75.7% | -44.2% | -34.5% | -18.3% | 27.8% | -56.8% | -42.2% | -85.5% |
| Return on assets (ROA) | -0.1% | -52.6% | -26.8% | -25.4% | -19.8% | -16.2% | 19.4% | -48.8% | -33.1% | -63.8% |
| Debt / equity | — | — | — | — | — | — | — | 0.02 | 0.03 | 0.03 |
| Current ratio | 4.86 | 6.74 | 3.95 | 2.92 | 2.62 | 7.92 | 2.73 | 6.37 | 3.63 | 3.53 |
| Revenue growth | 23,258.2% | -98.5% | -1.0% | 75.9% | 57.2% | -47.9% | 945.7% | -48.6% | 19,736.5% | -58.6% |
| EPS growth | — | — | — | — | — | -221.7% | — | — | — | — |